Table 4 Overall mortality rate by disease and treatment received
Overall mortality | ||
|---|---|---|
Survived n (%) | Died n (%) | |
Baseline hematological malignancies | ||
Acute lymphoid leukemia | 125 (74) | 44 (26) |
Chronic lymphoid leukemia | 340 (71.7) | 134 (28.3) |
Acute myeloid leukemia | 298 (60) | 199 (40) |
Chronic myeloid leukemia | 144 (89.5) | 17 (10.5) |
Myelodysplastic syndrome | 161 (57.7) | 118 (42.3) |
Low-intermediate risk | 77 (55.8) | 61 (44.2) |
High risk | 26 (54.2) | 22 (45.8) |
Not stated | 58 (62.4) | 35 (37.6) |
Hairy cell leukemia | 15 (65.2) | 8 (34.8) |
Hodgkin lymphoma | 120 (88.9) | 15 (11.1) |
Non-Hodgkin lymphoma | 739 (68.2) | 345 (31.8) |
Indolent | 354 (71.3) | 143 (28.7) |
Aggressive | 337 (65.3) | 179 (34.7) |
Not stated | 48 (67.6) | 23 (32.4) |
Essential thrombocythemia | 57 (82.6) | 12 (17.4) |
Myelofibrosis | 77 (63.1) | 45 (36.9) |
Polycythemia vera | 56 (80) | 14 (20) |
Systemic mastocytosis | 5 (83.4) | 1 (16.6) |
Multiple Myeloma | 458 (67) | 226 (33) |
Amyloidosis | 7 (87.5) | 1 (12.5) |
Aplastic anemia | 14 (70) | 6 (30) |
Last/ongoing treatment strategy before COVID-19 | ||
Anagrelide/Hydroxyurea | 106 (73.1) | 39 (26.9) |
Conventional chemotherapy | 423 (70.9) | 174 (29.1) |
Hypomethylating agents | 58 (41.2) | 83 (58.8) |
Immunotherapy only | 89 (71.2) | 36 (28.8) |
Immunochemotherapy | 595 (69.4) | 262 (30.6) |
Immunomodulators | 139 (63.8) | 79 (36.2) |
Targeted therapya | 453 (74.6) | 154 (25.4) |
Allogeneic HSCT | 130 (75.2) | 43 (24.8) |
Autologous HSCT | 54 (73) | 20 (27) |
CAR-T | 11 (52.4) | 10 (47.6) |
Radiotherapy | 9 (90) | 1 (10) |
Palliative/supportive measures | 122 (56) | 104 (46) |
Other | 17 (60.7) | 11 (39.3) |
Unknown | 28 (68.3) | 13 (31.7) |
No treatment | 382 (71) | 156 (29) |